Member News

Cloud computing support accelerates COVID-19 vaccine improvements

University of British Columbia
By University of British Columbia
May 15, 2021

For the last 12 months, University of British Columbia biochemistry and molecular biology professor Leonard Foster and his team have been studying how SARS-CoV-2 — the virus responsible for COVID-19 — attacks the human body, in hopes of developing a more targeted vaccine with fewer side effects.

Foster is confident that this technology will accelerate the development of second-generation vaccine candidates.

Foster-Leonard-445x426.jpg
University of British Columbia
 Leonard Foster and his team at UBC have been studying how SARS-CoV-2 —
 the virus responsible for COVID-19 — attacks the human body, in hopes of
developing a more targeted vaccine with fewer side effects.

"There are many different approaches to developing a vaccine," Foster said. "The current COVID-19 vaccines use a brute-force approach that throws everything we know about the virus at our immune system and hopes that there is something in there that will cause an immune response. But by studying how the virus actually causes disease, we can apply a more targeted approach and develop a more effective vaccine with minimal side effects."

Foster has been studying how pathogens such as bacteria and viruses cause disease in host organisms for more than a decade. He specializes in a technique called mass spectrometry that is used to identify and analyze specific proteins in pathogens that allow them to cause disease. Once those proteins are identified, the researchers can use the information to develop a targeted vaccine.

Before the pandemic, Foster was known for his work applying mass spectrometry to understand how pathogens affect honey bees in order to guide selective breeding for disease-resistant behaviours in bees. Now he's applying the same technology to better understand the novel coronavirus.

"By studying how the virus actually causes disease, we can apply a more targeted approach and develop a more effective vaccine with minimal side effects."
 Leonard Foster

"The types of experiments we do generate huge datasets that need to be analyzed and interpreted computationally," Foster said. "If someone was to use a pen, paper and a calculator, it might take them beyond the life of the universe to come up with results. With our existing resources, we may be able to come up with something in five to 10 years. But thanks to our collaboration with Microsoft, we have accessed cloud computing power that results in us being able to see results within months."

The research is supported by a Mitacs project, and leverages Microsoft's donation of its Azure cloud platform credits to the university through UBC Advanced Research Computing. This enabled Foster's team to pivot quickly to analyze huge amounts of new and existing data using an application that runs on the powerful cloud platform.

"The cloud computing resources have impacted our research instrumentally and significantly sped up our vaccine development," Foster said. "We've been able to do some experiments that were not conceivable with any of the other resources that we had."

Foster's work is especially important as scientists don't yet know how long immunity against COVID-19 will last with the current available vaccines due to a lack of data.

"By understanding the mechanism of this virus, we'll be able to develop the next generation of prevention and treatment methods, as well as laying the groundwork for the basic scientific knowledge in preparation for the next pandemic-causing virus," he said.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
University of British Columbia
University of British Columbia

This article was written by a staff member in the University of British Columbia Faculty of Medicine communications office.

Related articles

2025 PROLAB awardees announced
Marissa Locke Rottinghaus
How to choose a booster shot
Tina Hesman Saey, Science News

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Glaucoma model links immune signaling to disease progression
Journal News

Glaucoma model links immune signaling to disease progression

June 4, 2026

Researchers at Duke University determine genetic variations that could increase the risk of developing glaucoma.

Uncovering the molecular roots of fatty liver disease
Interview

Uncovering the molecular roots of fatty liver disease

June 3, 2026

Physician–scientist Silvia Sookoian discusses her path from hepatitis C care to MASLD research, her use of multi-omics to study steatotic liver disease, and how lipid metabolism and genetics are reshaping understanding of MASH and liver health.

Mitochondria shape kidney cell function
Journal News

Mitochondria shape kidney cell function

May 28, 2026

Researchers at the University of Washington, Seattle present the first quantitative comparison of mitochondrial interactomes between two epithelial cell types in the kidney.

Long-chain polyunsaturated fatty acids linked to postoperative delirium risk
Journal News

Long-chain polyunsaturated fatty acids linked to postoperative delirium risk

May 27, 2026

Researchers show that altered lipid metabolism may contribute to postoperative delirium, a condition linked to increased risk for long-term cognitive decline. The study explores potential disease mechanisms, which have yet to be understood.

Glycosylation patterns across antibody isotypes distinguish tuberculosis states
Journal News

Glycosylation patterns across antibody isotypes distinguish tuberculosis states

May 26, 2026

Researchers at Taipei Medical University present the first site-specific glycosylation analysis of immunoglobulins in elderly tuberculosis patients.

Blood glycome possibly predicts lifespan
Journal News

Blood glycome possibly predicts lifespan

May 21, 2026

Researchers at the University of Santiago de Compostela show that total serum N-glycome can predict mortality independent of traditional risk factors.